HENDERSON, Nev., Oct. 31,
2024 /PRNewswire/ -- VolitionRx Limited (NYSE
AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company,
has published a report, from its 'NETs in sepsis
management' symposium at ESICM Lives 2024 last month, which
concluded that Nu.Q® NETs could be used to predict
patients at greater risk of deteriorating from sepsis.
The symposium explored research findings from three large,
independent studies carried out at centers of excellence in
France, Germany, and the Netherlands, involving
more than 3,000 sepsis patients. All three clinical studies used
Volition's Nu.Q® NETs test to measure levels of circulating H3.1
nucleosomes in the bloodstream, a surrogate marker for Neutrophil
Extracellular Traps (NETs).
Professor Djillali Annane,
Professor of Medicine at University Paris Saclay-UVSQ and Chair of
Volition's ESICM Lives symposium said:
"The findings of these studies, summarized in Volition's
report, clearly and consistently show that an elevated level of
circulating H3.1 nucleosomes in sepsis patients reflects a
dysregulated immune response and is associated with an increased
risk of mortality, renal failure, respiratory failure, multi-organ
failure, and septic shock.
"As a physician, we now know that sepsis patients, with an
elevated H3.1 level on admission to intensive care, are at greater
risk of deteriorating and we need to act quickly.
"I believe that using the Nu.Q® NETs test to measure
elevated H3.1 nucleosome levels as a "treatable trait" in sepsis
management could be a game changer in modifying a patient's
trajectory. Introducing Nu.Q® NETs into hospitals could lead to new
ways of treating sepsis, improve patient survival and the quality
of life of survivors."
Dr Andrew Retter, Chief Medical
Officer at Volition, added:
"Nu.Q® NETs, Volition's nucleosome quantification technology, is
a simple, low-cost, accessible test to detect diseases associated
with NETosis. Although NETs play a critical role in our normal
immune response, elevated levels of NETs can lead to tissue damage
and in severe cases, sepsis, organ failure, and death.
"Being able to predict a sepsis patient's clinical course early,
by using Nu.Q® NETs in clinical practice, could significantly
enhance sepsis management, enabling physicians more time to
intervene and improve patient outcomes."
Volition is currently seeking to commercialize Nu.Q®
NETs and the findings from these latest studies, highlighted in the
company's ESICM symposium report, will support ongoing licensing
discussions with key industry stakeholders.
Download Volition's report, titled: 'Sepsis: a brighter hope for
tomorrow' here.
About Volition
Volition is a multi-national company focused on advancing the
science of epigenetics. Volition is dedicated to saving lives and
improving outcomes for people and animals with life-altering
diseases through earlier detection, as well as disease and
treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential not only to prolong the
life of patients, but also to improve their quality of life. For
more information about Volition's technology go to:
www.volition.com.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is included
in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, the potential uses, benefits and
effectiveness of Volition's Nu.Q® technology platform. Volition's
actual results may differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including, without limitation, results of studies testing the
efficacy of its tests. For instance, if Volition fails to develop
and commercialize diagnostic, prognostic or disease monitoring
products, it may be unable to execute its plan of operations. Other
risks and uncertainties include Volition's failure to obtain
necessary regulatory clearances or approvals to distribute and
market future products; a failure by the marketplace to accept the
products in Volition's development pipeline or any other
diagnostic, prognostic or disease monitoring products Volition
might develop; Volition's failure to secure adequate intellectual
property protection; Volition will face fierce competition and
Volition's intended products may become obsolete due to the highly
competitive nature of the diagnostics and disease monitoring market
and its rapid technological change; downturns in domestic and
foreign economies; and other risks, including those identified in
Volition's most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as other documents that Volition
files with the Securities and Exchange Commission. These statements
are based on current expectations, estimates and projections about
Volition's business based, in part, on assumptions made by
management. These statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that
are difficult to predict. Forward-looking statements are made as of
the date of this press release, and, except as required by law,
Volition does not undertake an obligation to update its
forward-looking statements to reflect future events or
circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos
are trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original
content:https://www.prnewswire.com/news-releases/multiple-studies-show-nuq-nets-test-could-predict-sepsis-patients-at-risk-of-deteriorating-302292798.html
SOURCE VolitionRx Limited
